Diacerein, its beneficial impact on chondrocytes and notable new clinical applications by Kaur, Daljit et al.
Braz. J. Pharm. Sci. 2018;54(4):e17534 Page 1 / 9
Brazilian Journal of 
Pharmaceutical Sciences
http://dx.doi.org/10.1590/s2175-97902018000417534
R
ev
ie
w
*Correspondence: Jaspreet Kaur. Assistant Professor, Rayat-Bahra In-
stitute of Pharmacy, Hoshiarpur, India. Phone: 09888992337. E-mail: 
jaspreet.meehnian@gmail.com
Diacerein, its beneficial impact on chondrocytes and notable new 
clinical applications
Daljit Kaur, Jaspreet Kaur1*, Sukhmeet Singh Kamal1
1Rayat-Bahra Institute of Pharmacy, Hoshiarpur, India
Diacerein (DCN) was obtained by diacetylation of an anthraquinone derivative rhein and was approved by 
FDA in 2008, in the treatment of osteoarthritis due to its inhibitory effect on proinflammatory cytokines, 
including IL-6 and IL-1β. It was synthesized in 1980s and marketed as a tablet in some European Union 
and Asian countries from 1994. Along with its great potential in the treatment of osteoarthritis, its other 
applications are also being explored day by day, such as in the treatment of psoriasis, epidermolysis 
bullosa, breast cancer, type 2 diabetes and periodontitis. The main aim of this review is to explore 
mechanism of action, various applications and side effects associated with DCN. This has been reviewed 
that apart from the risk of diarrhea on long-term administration of DCN, various clinical studies has also 
shown its modest benefits in treatment of various pathological conditions. Hence, DCN is emerging as 
a new and potentially safe derivative with maximum therapeutic efficacies and minimum side effects 
which can results in improving the living status of patients suffering from various inflammatory diseases. 
Keywords: Diacerein/osteoarthritis. Drug/chondroprotective. Diacerein/mechanism of action. Drug/
adverse effects. Diacerein/contraindications.
INTRODUCTION
DCN is emerging as a new chondroprotective agent 
used widely for symptomatic treatment of osteoarthritis 
(OA) i.e. degradation of joint cartilage and underlying 
bone as it prevents cartilage breakdown and slows down 
the progression of cartilage lesions (Pelletier et al., 2001; 
Jatwa, Kar, 2009). Several animal model studies and 
clinical trials have been conducted which demonstrated 
great role of DCN in the protection of cartilage matrix 
and symptomatic improvement among patients suffering 
from this degenerative disease, respectively (Pelletier 
et al., 2001). Dogs, sheep, guinea pig and rabbits were 
used in animal models (Pelletier et al., 2000). Several 
rheumatology societies have introduced DCN in their 
therapeutic guidelines as a treatment option in OA such 
as the European League Against Rheumatism (EULAR) 
and the Osteoarthritis Research Society International 
(OARSI) (Pavelka et al., 2016). DCN belongs to the class 
of anthraquinone derivatives found in Cassia gender plant, 
which has anti-inflammatory, analgesic and antipyretic 
activity (Magnard et al., 1993; Cardoso et al., 2017). In 
the International Union of Pure and Applied Chemistry, 
it is named as 4,5-diacetyloxy-9,10-dioxo-anthracene-
2-carboxylic acid (Elena, Newman, Gumus, 2009). 
DCN reduces the concentration of pro-inflammatory 
cytokines due to which it also has protective effect on 
granuloma induced cartilage breakdown. DCN belongs 
to BCS class II with poor aqueous solubility of 3.197 
mg/mL due to which only 35-56% of drug reaches the 
systemic circulations (Parekh, Paun, Soniwala, 2017). 
Both DCN and its active metabolite, rhein are considered 
powerful inhibitors of cytokines synthesis (IL-1β) and 
metalloproteases (collagenase and stromelysin) which 
are main inflammatory mediators involved in cartilage 
breakdown (Pelletier et al., 2000). DCN come under 
disease modifying osteoarthritis drugs (DMOADs), 
which reduces the severity of disease and restrains 
the progression rate of degraded cartilage. DCN also 
upregulates the expression of transforming growth 
factors (TGF-β1 and TGF-β2), even in the absence of 
IL-1β. Along with this it also antagonizes the IL-1β 
triggered mitogen-activated protein kinase signaling 
cascades of articular chondrocytes and stimulates cartilage 
regeneration process (Frohnwiesery et al., 2014). In March 
2014, the European Medicines Agency (EMA) conducted 
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a review on the request of French medicines agency, which 
was mainly concerned with frequency and severity of 
diarrhea and liver disorders in OA patients. The EMA’s 
Pharmacovigilance Risk Assessment Committee (PRAC) 
questioned the limited clinical benefits associated with 
DCN, which did not outweigh its risks and they restricted 
the use of DCN containing medicines for patients aged 
≥65. In order to minimize these risks, this was advised 
that patients should start treatment on half of the normal 
dose (i.e. 50 mg/day instead of 100 mg/day) for first 
2-4 weeks and should stop taking DCN on account of 
diarrhea (Panova, Jones,2015; Pavelka et al., 2016). 
The Pharmacovigilance Risk Assessment Committee 
of European Medicines Agency, the European Society 
for Clinical and Economic Aspects of Osteoporosis and 
Osteoarthritis (ESCEO) confirmed that after first month of 
treatment with DCN and non-steroidal anti-inflammatory 
drugs (NSAIDs), the resulted efficacy was same but 
superior to that of Paracetamol. For patients in whom 
NSAIDs or Paracetamol are contraindicated, ESCEO has 
recommended DCN as first line therapy in the treatment 
of OA. Based on these evidences ESCEO concluded that 
the benefit–risk balance of DCN remains positive in the 
symptomatic treatment of hip and knee OA (Pavelka 
et al., 2016). In 2015, a study was conducted in which 
efficacy of DCN was found to be maximum as compared 
to Diclofenac sodium in OA induced albino rats (Osman et 
al., 2015). Diacerein is a slow acting drug, whose response 
is attained gradually (4-6 weeks), but after withdrawal, its 
symptomatic effect persists for several months (4-8 weeks) 
(Medhi et al., 2007; Akhter et al., 2015).
DIACEREIN AS A POTENTIAL SALVAGER OF 
CHONDROCYTES IN OSTEOARTHRITIS
Osteoarthritis is derived from Greek words “Osteon” 
meaning the bone, “arthon” meaning joint and the suffix 
“itis” means inflammation (Aigner, Schmitz, 2011). 
This chronic disease is most common form of arthritis 
among older adults, also known as degenerative arthritis 
or osteoarthrosis. A degenerative disease is generally 
considered as a clinical syndrome in which low grade 
inflammation results in painful joints (Woolf, Pfleger, 
2003). It affects about 9.6% men and 18% women, aged 
>60 years, post-menopausal women are more susceptible 
to OA as compared to men of the same age group (Woolf, 
Pfleger, 2003; Tanamas et al., 2011). This musculoskeletal 
disease is considered as a main cause of chronic disability 
in USA and has been expected as fourth leading cause of 
disability by the year 2020 (Woolf, Pfleger, 2003). 
OA can affect any joint of human body, but it occurs 
most often in knees, hips, lower back, neck, small joints of 
the fingers, bases of the thumb and big toe. With each decade 
of life the prevalence of symptomatic knee OA increases, 
as its annual incidences being highest between 55 and 64 
years old. In 2010, the prevalence of symptomatic knee 
OA in patients aged ≥45 had been estimated between 5.9% 
to 13.5% in men and 7.2% to 18.7% in women, whereas 
approximately 10 million adults had symptomatic knee OA. 
As the world’s population continues to age, it is estimated 
that degenerative joint disease disorders such as OA will 
impact at least 130 million individuals around the globe 
by the year 2050 (Arthritis Foundation, 2017). Treatment 
options for OA are an actual challenge due to the poor self-
healing capacity of cartilage (Frohnwieser et al., 2017). The 
most effective class of drugs for the symptomatic relief in 
severe cases of OA is NSAIDs. Although NSAIDs have 
lower chances of gastric irritation but long-term use could 
increase the chance of cardiovascular disease (Flood, 2010). 
Oral steroids and some rubefacients such as capsaicin and 
intra-articular hyaluronan injections are also used for the 
treatment of OA. Despite of their modest benefits they are 
not recommended because of their high rate of side effects 
(Chen et al., 2008).
FIGURE 1 - Metabolism of DCN.
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So, development of effective alternatives to NSAIDs 
is the need of the hour due to which new drug molecules 
are emerging. DCN, glucosamine sulfate, glucosamine 
hydrochloride, chondroitin sulfate, hyaluronic acid and 
avocado soybean unsaponifiables (ASU) are second 
line drugs for the treatment of OA which are classified 
as symptomatic slow acting drugs (SYSADOA). As 
compared to NSAIDs and placebo, DCN is effective in 
the symptomatic OA as well as any structural changes 
occurring in OA of the knee (Kongtharvonskul et al., 
2015), hence EULAR has recommended DCN as IL-1β 
inhibitor, in its guidelines in 2003. Previous systematic 
reviews on DCN have showed its higher efficacy in 
reducing the pain and Lequesne index but increased risk 
of diarrhea as compared to placebo (Rintelen, Neumann, 
Leeb, 2006; Bartels et al., 2010). From 1982 several trials 
have been conducted on DCN to evaluate its efficacy and 
severity in the treatment of OA and since 1984 DCN has 
been marketed all over the world, with exception in USA 
(Fidelix et al., 2014).
DCN is different from the conventional NSAIDs due 
to the following two reasons:
•	 It prevents the loss of hydroxiproline and proteogly-
cans present in the joint cartilage by stimulating the 
production of TGF-β (Mahajan et al., 2006; Medhi 
et al., 2007). 
•	 DCN does not have any inhibitory effect on phos-
pholipase-A2 (PLA2), cyclooxygenase (COX), lipox-
ygenase (LOX) and prostaglandins (PGs) synthesis 
due to which it does not cause any gastro-duodenal 
toxicity (Pelletieret al., 1998; Zaki et al., 2013). 
MECHANISM OF ACTION
IL-1β is a biologically inactive precursor which is 
synthesized in the cell. To exit from the cell, it requires 
proteolytic cleavage which further allows the activation 
of cytokine. IL-1-converting enzyme (ICE) also known 
as caspase-1, which is an endopeptidase localized 
intracellularly, completes the above stated process. The 
level of ICE gets elevated in OA due to which the secretion 
as well as activity of the cytokine gets increased. Hence, 
DCN reduces the level of ICE which results in inhibition 
of IL-1β (Moldovan et al., 2000; Pelletier, Pelletier, 2010). 
In case of human OA chondrocytes, IL-1 promotes the 
expression of inducible nitric oxide synthase, enhances the 
release of PGE2 and stimulates matrix metalloproteinases 
(MMPs) which results in joint degradation (Rao et al., 
2009). The levels of collagenase and stormelysin get 
increased in the synovial fluid due to activation of MMPs 
which results in cartilage destruction (Yaron, Shirazi, 
Yaron, 1999). IL-1 activates monocytes/macrophages 
which results in inflammation, by inducing fibroblasts 
proliferation it causes synovial pannus formation, 
breakdown of cartilages by activation of chondrocytes 
and bone resorption by activation of osteoclasts (Mahajan 
et al., 2006).
DCN improves various pathological conditions that 
are responsible for OA by following mechanisms:
i. By selective inhibition of IL-1, DCN improves all 
the pathological conditions responsible for joint 
degeneration in human volunteers experiencing 
the OA of finger joint and knee. DCN also inhibits 
the IL-1 induced expression of enzymes which are 
responsible for the destruction of cartilage (Mahajan 
et al., 2006; Felisaz et al., 1999).
ii. Nuclear factor kappa B (NF-κB) and activator pro-
tein-1 (AP-1) are transcription factors responsible 
for the expression of several pro-inflammatory genes 
by chondrocytes, DCN retards the binding of these 
transcription factors (Leeb, 2010).
iii. As it has a property of disease modifying agent 
therefore DCN improves the expression of TGF-β1 
and TGF-β2 which favours the conditions such as 
matrix synthesis and turnover in articular chondro-
cytes. DCN reduces the turnover of chondroitin-
4-sulphate, which causes great decrease in the ratio 
of chondroitin-6-sulphate to chondroitin-4-sulphate. 
By this mechanism DCN can protect the proteogly-
can aggrecan which is composed of chondroitin sul-
phate and keratin sulphate chains ultimately helpful 
in allowing articular cartilage to resist compression 
under load (Medhi et al., 2007).
iv. Drug is a potent and selective inhibitor of N-acyl-
ethanolamine-hydrolyzing acid amidase (NAAA), 
which catalyzes the hydrolysis of palmitoyletha-
nolamide (PEA). PEA is a protective endogeneous 
mediator, gets stimulated during inflammatory 
and neurodegenrative conditions to exert an anti-
inflammatory as well as analgesic action. PEA 
also acts by down regulating the mast cell degra-
dation through an Autocoid Local Inflammation 
Antagonism (ALIA) mechanism (Petrosinoet al., 
2014).
v. DCN also retards the superoxide production, che-
motaxis and phagocytic activity of neutrophils by 
having an additional effect on macrophages migra-
tion and phagocytosis. DCN also reduces the num-
ber of urokinase receptors on chondrocytes upto 
normal level and reduces the fibrinolytic activity 
in synovial fluid (Pelletier et al., 2000; Mahajan et 
al., 2006).
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vi. DCN shows inhibitory effect on production of col-
lagenases and also promotes the synthesis of proteo-
glycans which are inhibited by IL-1 (Felisaz et al., 
1999).
METABOLISM AND ELIMINATION
After oral administration of 50 mg dose of DCN, 
19.6±11.3% of its non-conjugated metabolite gets 
excreted in the urine while 62.7±13.5% was in the form 
of glucuroconjugated rhein and 18.6±5.6% in the form of 
sulphuronoconjugated rhein (Louchahi, Nicolas, Petitjean, 
1991; Mahajan et al., 2006; Medhi et al., 2007). 
PHARMACOLOGICAL USE OF DIACEREIN IN 
VARIOUS PATHOLOGICAL CONDITIONS 
OTHER THAN OSTEOARTHRITIS
Jatwa and Kar (2009), provided an evident study, 
according to which various adverse effects (such as irritant 
induced altered glucose levels and lipid metabolism, 
oxidative stress and decreased levels of thyroid hormones) 
were found to be reversed in carrageenan treated animals 
on administration of DCN for 21 days.
Ramos-Zavala et al. (2011), had reported increased 
insulin secretion in patients who were on DCN therapy, 
reason being is inhibition of both cytokines IL-1β and 
TNF-α, which plays an important role in the apoptosis 
of β-cell. 
Recently, a randomized clinical trial has been 
conducted according to which DCN reduced the mean 
HbA1c levels, with peak effect at the 24th week of 
treatment. The drug was well tolerated and might be 
indicated as adjunct treatment of patients with type 2 
diabetes, particularly in those with OA (Cardoso et al., 
2017). As a low-grade chronic inflammatory state was 
observed in obesity and type 2 diabetes. In type 2 diabetes, 
a great decrease in insulin secretion has been observed due 
to presence of some pro-inflammatory cytokines (TNF- 
α, IL-1β and IL-6), which causes apoptosis of β cells. 
In previous studies, activity of DCN had been studied 
in various animal models of obesity and diabetes, which 
demonstrated down regulation of these pro- inflammatory 
cytokine expression, which resulted in improved glucose 
tolerance and lower fasting glycemia levels (Cardoso et 
al., 2017; Villar et al., 2017).
TABLE I - Urinary excretion pharmacokinetic parameters of 
DCN after oral administration (Medhi et al., 2007)
Parameter Estimated value
Apparent availability of rhien by urinary 
data assessment
35%
Maximum plasma concentration (Cmax), 
after 2.2 hrs
3.2 mm/L
Area under the plasma concentration-time 
curve (AUCo)
21.3 mg/L/h
Apparent volume of distribution (Vd) 13.2 L
Apparent total plasma clearance (CLt) 1.6 L/h
Renal clearance (CLr) 0.13 L/h
Elielimination half life (t1/2) 4.3 h
FIGURE 2- Anabolic effect of DCN (Medhi et al., 2007).
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crevicular fluid (GCF) of the patients (45 subjects divided 
into three groups) suffering from chronic periodontitis.
EXPLORED ADVERSE EFFECTS OF DIACEREIN
As rhein is an active metabolite of DCN and due 
to presence of anthraquinone ring in rhein it has anti-
inflammatory, hepatoprotective, nephroprotective, 
chondroprotective, antioxidant, anticancer, antidiabetic, 
a n t i m i c r o b i a l ,  p u rg a t i v e  a n d  l i p i d  l o w e r i n g 
pharmacological activities (Yan et al., 2015). Despite of 
these pharmacological activities, its incomplete absorption 
in the gut causes undesirable side effects such as laxative 
action, diarrhea and abdominal pain (Dubey et al., 2009). 
Long term administration causes undesirable side effects 
due to accumulation of DCN and rhein. When rhein reaches 
the colonic site, it gets converted into the rhein-9-anthrone 
which is particularly responsible for the soft stools (Nakhat 
et al., 2015). On 100 mg of oral administration of DCN 
daily, 46% patients had been reported the incidence of 
diarrhea (Mandawgade et al., 2016). 
The incomplete absorption of DCN from gut 
produces diarrhea by various mechanisms such as:
Intake of DCN causes the inhibition of IL-1β which 
could be directly related to diarrhea. Kruse et al., (2008), 
provided a clinical evidence of increased concentration 
of IL-1β at the beginning of dysentery in pigs and 
Escherichia coli induced diarrhea. Any infection in the gut 
triggers the immune system which causes the release of 
cytokine and TNF-α as a part of immune system. Hence, 
the DCN receiving patients became less susceptible to 
fight against any infection related to gut, due to which 
incidence of diarrhea increases in such group of patients 
as DCN directly inhibits the IL-1β which is present in the 
gut (Gwee et al., 2003; Kruse et al., 2008; Bartels et al., 
2010). Another major cause of diarrhea is the capability 
of DCN to induce prostaglandin synthesis such as PGE2 
which increases the amount of gut fluid due to which the 
motility of the gut increased (Pelletier et al., 2000; Gupta, 
Datta, 2012).
Other major adverse effect associated with DCN 
is the reactivation of tuberculosis in patients receiving 
DCN. As TNF-α and IL-1 has played an important role 
in the constitution of granulomas and immune protection 
during the early phase of granulomatous infection like 
TB. Several in vitro studies demonstrated that apart from 
IL-1 inhibition, DCN also inhibits other interleukins such 
as IL-2 and IL-12 which decreases the body’s resistance 
to tubercle bacilli especially during the first 2 months of 
infection. IL-12 inhibition has significantly decreased 
the lytic activity of polymorphoneuclear leukocytes and 
Kumar et al. (2011), prepared the DCN cream which 
was found to be effective in the treatment of psoraisis in 
those patients who did not respond to other medicines.
Mohan et al. (2017), explained the role of DCN 
in psoriasis, as psoriasis has increased IL-1 activity 
which also increased the risk of atherosclerosis and 
cardiovascular morbidity. DCN reverses the pro-
atherogenic and pro-inflammatory gene regulation 
caused by IL-1 in endothelial cells and keratinocytes, 
potentially preventing progression of skin inflammation 
and inflammation induced atherosclerosis.
Torina et al., (2015) investigated the effect of 
DCN on ventricular remodeling. The study estimated 
that treatment with DCN once a day for 4 weeks after 
myocardial infarction improved ventricular remodeling 
by promoting lower end-systolic and end-diastolic left 
ventricular volumes. DCN also reduced the fibrosis in 
the left ventricular, as DCN was associated with partial 
blockage of the NF-κB pathway.
Along with chondroprotective activity, DCN 
α-aminophosphonate conjugate has been reported to have 
anti-proliferative activities on tumor cells. A study was 
conducted, which revealed for the first time that DCN 
decreases the viability of human chondrosarcoma cells and 
induces G2/M cell cycle arrest, in dose dependent manner, 
by down-regulation of CDK1/cyclin B1 (Lohberger et al., 
2015). In 2015, in vivo antitumor potential of DCN for 28 
days in dose dependent manner was conducted in MDA-
MB-231 xenograft model, which demonstrated that DCN 
caused dose-dependent anti-proliferative effect on breast 
cancer cells MCF-7, MDA-MB-231, MDA-MB-468 
and T47D. The current study presented that targeted 
inhibition of IL-6/IL-6R-mediated STAT3, MAPK and 
Akt signaling by DCN, provides new therapeutic regimens 
for breast cancer. As high level of IL-6 presents in tumor 
microenvironments which promotes several oncogenic 
signaling (Bharti et al., 2016).
In 2013, a randomized controlled pilot study was 
conducted, in which DCN showed positive results against 
epidermolysis bullosa within 2 weeks (Wally et al., 2013). 
DCN is considered as effective in the treatment of 
periodontal disease because of inhibition of the release of 
various inflammatory mediators like pro-inflammatory 
cytokines (IL-1, IL-6, TNF-α), lytic enzymes like matrix 
metalloproteinases (MMPs) and prostaglandins (PG). 
Efficacy of DCN in periodontitis has been evaluated by 
using rats and results showed great decrease in IL-1β level 
from baseline to two weeks as well as from baseline to 
four weeks (Zaki, Aly, Mahmoud, 2015). Recently a study 
was conducted by Enji et al. (2016), which revealed great 
decrease in the levels of IL-1 and osteocalcin in gingival 
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mononuclear cells against M. tuberculosis infected cells 
(Gupta, Datta, 2012). 
CONTRAINDICATIONS
Daily dose of DCN should be reduced to half for 
patients having severe kidney failure and creatinine 
clearance less than 30ml/min. 
DCN is contraindicated in following conditions:
•	 Severe liver failure (Art50-DL, 2012; Artrodar®, 
CMDh, 2014)
•	 Inflammatory organic bowel disease such as ulcer-
ative colitis and crohn's disease
•	 Intestinal or partial obstruction
•	 Abdominal pain syndromes of indeterminate etiology
•	 Episodes of hypersensitivity to rhein or other anthra-
quinine derivatives
SPECIAL WARNINGS AND PRECAUTIONS 
FOR USE
DCN should not be recommended during pregnancy, 
lactation and to children under age of 15 years. DCN 
capsules must not be administered in case of congenital 
galactosemia, glucose or galactose malabsorption 
syndrome or lactase deficiency because of the presence 
of lactose. DCN should not be recommended to patients 
already receiving ACE inhibitors or diuretics as there is 
an increased risk of salt, water depletion which may lead 
to dehydration and hypokalaemia as DCN causes diarrhea 
(Art50-DL, 2012).
DRUG INTERACTIONS 
CONCLUSION
DCN is emerging as a new alternative to NSAIDs as 
it does not have any effect on COX-II and hence no gastric 
irritation. Along with its effective use in the treatment 
of OA, DCN is a potential molecule in the treatment of 
psoraisis, epidermolysis bullosa, rheumatoid arthritis and 
periodontitis. The main toxicity caused by DCN is mild to 
moderate diarrhea, of which there is an increasing risk with 
increasing dose and duration. Further research is needed 
for effective delivery of DCN in OA because when it is 
administered at dose 100-150 mg daily, the concentration 
of drug that reaches the synovial fluid ranges from 10-7 
to 10-4 M. As very low concentration of drug reaches to 
synovial fluid, this leads to its slow onset of action (about 
3 months) after the start of therapy.
From this extensive review it has been concluded 
that DCN is a potential drug molecule and it is imperative 
to apply various pharmaceutical techniques to develop a 
robust dosage form with effective drug delivery at low 
possible dose without any side effect.
TABLE III - Interaction of DCN with other drugs
Interaction with Inference Reference
Antacids 
(aluminium, 
calcium and 
magnesium 
salts, oxides or 
hydroxides)
Decreased 
digestive 
absorption of 
DCN. Hence, 
antacids should 
be taken with the 
interval of 2 hours 
from DCN, if 
necessary
Art50-DL, 2012
Excess fibres or 
phytates
Modified 
intestinal transit 
or the quality of 
intestinal content
Artrodar® CMDh, 
2014
Antibiotics or 
chemotherapy
Increased 
enterocolic events
Artrodar® CMDh, 
2014
Diuretics 
(high ceiling 
loop diuretics 
and thiazides) 
andcardiac 
glycosides 
(digitoxin, 
digoxin)
Increased risk of 
arrhythmias WHO, 2014
TABLE II - Uses and adverse effects of DCN
Uses of DCN Adverse effects of DCN Reference
Osteoarthritis 
Coxathrosis 
Gonarthrosis
Diarrhea
Shafshak et al., 
2012; Bruyere et al., 
2008
Rheumatoid 
arthritis
Intense yellow 
coloured urine
Shafshak et al., 
2012
Psoriasis Stomach pain
Napoli, 2003; 
Shafshak et al., 
2012
Epidermolysis 
bullosa
Nausea and 
vomiting
Wally et al., 2013; 
Shafshak et al., 
2012
Periodontitis Heartburn
Zaki, Mahmoud, 
Aly, 2015; Shafshak 
et al., 2012
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